Dr. Dan Peer
Dr. Dan Peer is a principal investigator and professor who leads an NIH- and ERC-funded laboratory at Tel Aviv University. Prof. Peer completed his education in biochemistry and biophysics at Tel Aviv University, with internships both at Cambridge University, UK (Cesar Milstein Lab) and MIT, Cambridge, MA, USA (Robert Langer lab). From 2005-2008, he worked at Harvard Medical School (M. Shimaoka and T. Springer). He then joined the Department of Cell Research and Immunology, of the Faculty of Life Sciences at TAU to establish the laboratory of Precision Nanomedicine. Prof. Peer’s research was one of the first to demonstrate systemic delivery of RNA interference (RNAi) molecules using targeted nanocarriers to the immune system, and the first to utilize RNAi for in vivo validation of new drug targets within the immune system.
Prof. Peer’s work was pioneering also in the field of gut inflammation and he was involved in the development of antibodies that block lymphocytes homing into the gut during inflammatory bowel disease. He has received numerous awards; among them, he was recognized by the Kenneth Rainin Foundation by their Innovator (2010) and Breakthrough (2011-2013) Awards for his pioneering work in inflammatory bowel diseases and by the AAAS for his development of the Gagomers platform technology for targeted drug delivery for immuno-oncology and most recently the 2017 Nanos Award from CLINAM 10th, Basel, Switzerland.
Dr. Peer is the Chair of Tel Aviv University Cancer Biology Research Center, which includes 17 affiliated hospitals surrounded Tel Aviv and he oversees the science and activity of preclinical and clinical work in this Center. He is also the Managing Director of Tel Aviv University’s new Translational Medicine Center.
Dr. Peer holds around 100 pending and granted patents. He co-founded four companies based on his work aiming to bring the area of nanomedicine into clinical practice, with two of them in the clinic. Dr. Peer is a member of the Israel Young Academy of Science.